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Background and aims: Lipocalin-2 (Lcn2) is a glycoprotein which can be secreted by immune cells.
Several studies in humans have suggested Lcn2 can be used as a biomarker for the detection of unstable
atherosclerotic lesions, partly as it is known to interact with MMP-9.
Methods: In this study, we generated Ldlr-/-Lcn2-/- mice to assess the functional role of Lcn2 in different
stages of atherosclerosis. Atherosclerotic lesions were characterized through histological analysis and
myeloid cell populations were examined using ﬂow cytometry.
Results: We show that Ldlr-/- Lcn2-/- mice developed larger atherosclerotic lesions during earlier stages of
atherosclerosis and had increased circulating Ly6Chi inﬂammatory monocytes compared to Ldlr-/- mice.
Advanced atherosclerotic lesions from Ldlr-/- Lcn2-/- mice had decreased necrotic core area, suggesting
Lcn2 deﬁciency may affect lesion stability. Furthermore, MMP-9 activity was diminished in plaques from
Ldlr-/-Lcn2-/- mice.
Conclusions: Altogether, these ﬁndings suggest that Lcn2 deﬁciency promotes lesion growth in earlier
stages of the disease while it decreases MMP-9 activity and necrotic core size in advanced
atherosclerosis.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The development of atherosclerosis and subsequent athero-
sclerotic plaque destabilization are the main underlying pathology
of (ischemic) heart disease. Therefore, early detection of unstable
atherosclerotic plaques using biomarkers could prove useful to
reduce the incidence of acute cardiovascular syndromes. A poten-
tial candidate to use as a biomarker for unstable atherosclerosis is
lipocalin-2 (Lcn2), which is also known as 24p3 in mice and as
neutrophil-gelatinase associated lipocalin (NGAL) in humans.
Lcn2 is a secreted glycoprotein, which was originally identiﬁed
as a product of human neutrophils [1,2]. Upon bacterial infection,
Lcn2 functions as a bacteriostatic agent by sequestering iron from
bacterial siderophores, such as enterobactin [3]. During inﬂam-
mation, Lcn2 can act as an inﬂammatory mediator by binding N-
formylmethionyl-leucyl-phenylalanine and leukotriene B4 (LTB4)J. Amersfoort).
B.V. This is an open access article u[4]. Interestingly, Lcn2 itself can also act as a chemoattractant for
neutrophils during infection [5]. Furthermore, Lcn2 can form a
complex with matrix metalloproteinase (MMP)-9, thereby pre-
venting it from being inhibited by tissue inhibitor of
metalloproteinases-1 [6]. Active MMP-9 inside atherosclerotic le-
sions can degrade extracellular matrix and may thus contribute to
advanced plaque instability [7,8]. By stabilizing active MMP-9, Lcn2
may contribute to the degradation of the ﬁbrous cap and destabi-
lization of atherosclerotic plaques in general [9]. In line, several
reports suggest that serum NGAL levels can be used to predict the
incidence of cardiac events. Serum NGAL levels were for example
shown to correlate with levels of C-reactive protein and to predict
major adverse cardiac event (MACE) as well as all-cause mortality
in patients with a history of CVD [10e12]. Furthermore, serum
NGAL/MMP-9 complex levels are associated with MACE in patients
1 year after coronary angiography [13]. Serum NGAL levels were
higher in patients with angiographically conﬁrmed coronary artery
disease compared to patients without. Additionally, serum NGAL
levels were associated with the number of diseased vessels,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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disease [14]. Furthermore, patients with symptomatic atheroscle-
rosis in carotid arteries were shown to have higher levels of serum
NGAL as compared to asymptomatic patients [15]. mRNA expres-
sion of NGAL was also elevated in atherosclerotic plaques of pa-
tients with symptomatic carotid atherosclerosis compared to
asymptomatic patients [16]. Local NGAL protein levels were also
demonstrated to be elevated in unstable versus stable plaques and
NGAL content correlated speciﬁcally with MMP-9 activity [17]. In
mouse models for atherosclerosis, Lcn2 was shown to colocalize
with MMP-9 in atherosclerotic plaques [18].
Lcn2 is actually a very pleiotropic protein, as it is also associated
with the development of metabolic diseases, which can subse-
quently contribute to cardiovascular disease [19]. Serum NGAL
levels were elevated in obese individuals compared to lean controls
and correlated with insulin resistance [20]. Furthermore, NGAL
expression was shown to be elevated in visceral adipose tissue of
obese individuals compared to non-obese controls. In adipose tis-
sue, enzymatic activity of NGAL/MMP-9 complexes was increased
in obese individuals compared to lean controls [21]. Despite the
evidence from literature which suggests that Lcn2 is associated
with the development of atherosclerosis and obesity, there are still
many questions regarding the exact pathophysiological role for
Lcn2 in atherogenesis. Mechanistic insights gained from experi-
mental models studying Lcn2 in multiple stages of atherosclerosis
could contribute to the applicability of Lcn2 as a biomarker for early
detection of unstable atherosclerosis and coronary artery disease.
In this study, we thus aimed to investigate the contribution of Lcn2
to different stages of diet-induced atherosclerosis. We show here
that Lcn2 has a stage-dependent contribution to experimental
atherosclerosis as it seems to limit lesion development, whereas it
potentially contributes to plaque instability in more advanced
stages of atherosclerosis.
2. Materials and methods
2.1. Mice
All animal work was performed according to the guidelines of
the European Parliament Directive 2010/63EU and the experi-
mental work was approved by the Animal Ethics committee of
Leiden University. Ldlr deﬁcient (Ldlr-/-) mice were originally pur-
chased from Jackson Laboratory and further bred in the Gorlaeus
Laboratory in Leiden, The Netherlands. Lcn2 deﬁcient (Lcn2-/-) mice
were kindly provided by Dr. Mak [22] and were backcrossed to
Ldlr-/- mice to generate Ldlr-/- Lcn2-/- mice. The animals were kept
under standard laboratory conditions and were fed a normal chow
diet and water ad libitum, unless otherwise stated.
2.2. Microarray on non-constrictive collar-induced carotid
atherosclerosis
To determine Lcn2 gene expression levels during atherosclerotic
lesion development, RNAwas extracted fromatherosclerotic lesions
as previously described [23]. In short, Ldlr-/- mice were fed a
Western-type diet (WTD) (Special Diet Services) two weeks before
surgery and throughout the experiment. To determine the gene
expression levels in plaques, atherosclerotic carotid artery lesions
were induced by perivascular collar placement as described previ-
ously [24]. Both common carotid arteries were excised, snap-frozen
in liquid nitrogen and stored at 80 C until further use. Three ca-
rotid artery segments carrying carotid plaques from 2, 4, 6, 8 or 10
weeks after collar placement (t¼ 2 until t¼ 10) were pooled for
each sample and homogenized by grounding in liquid nitrogenwith
a pestle [25,26]. Carotid arteries without atherosclerosis from micewhichwere only fed aWTD for twoweeks served as a control (t¼ 0).
Per time point,weperformed amicroarray on three pooled samples.
An additional collar-induced atherosclerosis experiment with a
similar design was performed in parallel to generate RNA samples
for real-time quantitative PCR analysis as described below. In this
setup we again pooled three carotids into one sample and gener-
ated the following pooled samples per time point: for t¼ 0 (n¼ 4),
for t¼ 2,4 or 6 (n¼ 5) for t¼ 8 (n¼ 4) and for t¼ 10 (n¼ 3). In
addition we also stored carotids from Ldlr-/- mice that had not been
fed a Western type diet and these carotids were used to compare
with the t¼ 0 time point, which reﬂects carotids that were in a
hyperlipidemic environment but did not contain atherosclerotic
plaques. Total RNA was extracted from the tissue homogenates
using Trizol reagent according to manufacturer's instructions
(Invitrogen). Gene expression proﬁles were generated using the
Illumina Bead-Chip Whole Genome Microarray platform
(ServiceXS).
2.3. Atherosclerosis
Diet-induced atherosclerosis was established by feeding female
Ldlr-/- and Ldlr-/- Lcn2-/- mice from 9 to 12 weeks of age a WTD
containing 0.25% cholesterol and 15% cocoa butter (Special Diet
Services). Atherosclerosis was induced for either 6 or 12 weeks to
study atherosclerotic lesions in an earlier or more advanced stage.
At the end-point of the study, the mice were ane-sthetized by
subcutaneous injections with ketamine (100mg/mL), sedazine
(25mg/mL) and atropine (0.5mg/mL) after which their vascular
system was perfused with PBS at a continuous low ﬂow via heart
puncture in the left ventricle. The hearts were collected to examine
the atherosclerotic lesions in the aortic root through histological
and morphometric analysis.
2.4. Histological and morphometric analysis of atherosclerotic
lesions
All hearts were embedded in O.C.T. compound (Sakura) and
sectioned horizontally to the aortic axis and towards the aortic
arch. Upon identiﬁcation of the aortic root, deﬁned by the trivalve
leaﬂets, 10 mm sections were collected. Mean plaque size (in mm2)
was calculated from ﬁve sequential sections, displaying the highest
plaque content, using an Oil-red-O staining (Sigma), which stains
neutral lipids. Monocytes andmacrophages were visualized using a
Moma2 antibody (1:1000, Serotec) and an alkaline phosphatase
conjugated secondary antibody (1:100, Sigma). To quantify smooth
muscle cell content, smooth muscle cells were visualized by an a-
smooth muscle cell actin (aSMA) staining (1:1000, Abcam) and a
horseradish peroxidase conjugated secondary antibody. Collagen
content inside the plaques was quantiﬁed using a Mason's Tri-
chrome staining (Sigma). In the same sections, necrotic areas were
identiﬁed as intimal a-cellular, debris-like areas. Neutrophils were
stained for using the naphtol AS-D chloroacetate esterase staining
kit (Sigma). Image quantiﬁcation was performed blinded for ge-
notype using the Leica Image analysis system (Leica Ltd). Apoptotic
cells were stained using the In situ Cell Death Detection Kit (Sigma)
per the manufacturer's protocol. On the same sections, macro-
phages were stained using a rat-anti-mouse F4/80 antibody (1:100,
Biorad) and an Alexa Fluor 647 conjugated goat-anti-rat IgG as a
secondary antibody (1:100, Thermo Fisher Scientiﬁc). Nuclei were
visualized using Fluoroshield mounting medium with DAPI
(Sigma). To quantify apoptosis, TUNEL positive nuclei were quan-
tiﬁed inside atherosclerotic lesions. To quantify apoptotic macro-
phages, TUNEL positive nuclei which were colocalized with F4/80
staining were quantiﬁed. Quantiﬁcation of apoptosis was per-
formed using a Nikon TiE 2000 confocal microscope.
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Non-ﬁxed hearts were snapfrozen on dry ice and stored until
further use. 10 mm cryosections were acquired from the three-valve
area and air dried for 1e2 h before storage at 80 C. Cryosections
were washed in reaction buffer (150mM NaCl, 5mM CaCl2, 50mM
Tris-HCl, pH¼ 7.6) and incubated in reaction buffer containing
30 mg/mL DQ-Gelatin (Molecular probes) and 20mM MMP2-
inhibitor OA-Hycis-9-Octadeconoyl-N-hydroxylamide (Merck Mil-
lipore) overnight at 37 C. 1mM 1,10-phenantrolin is an MMP in-
hibitor and thus served as a control. After incubation, the sections
were washed in reaction buffer and subsequently incubated in 0.5%
Chicago Sky Blue (Sigma) for 5min to dampen autoﬂuorescence.
Finally, the slides weremounted in Fluoroshield mediumwith DAPI
(Sigma) and imaged using the Leica Image analysis system (Leica
Ltd).
2.6. Real-time quantitative PCR
RNA was extracted from mechanically disrupted common ca-
rotid arteries or aortic arches by using Trizol reagent according to
manufacturer's instructions (Invitrogen) after which cDNA was
generated using RevertAid M-MuLV reverse transcriptase per the
instructions of the manufacturer (Thermo Scientiﬁc). Quantitative
gene expression analysis was performed using Power SYBR Green
Master Mix on a 7500 Fast Real-Time PCR system (Applied Bio-
systems). Gene expression was normalized to housekeeping genes
(Supplementary table 1).
2.7. Immunoblot
Atherosclerotic aortic arches were snapfrozen in liquid nitrogen
and stored at 80 C until further use. For protein isolation, tissue
samples were homogenized by mechanical disruption and lysed
with 1xRIPA (Cell Signaling Technology) supplemented with
cOmplete™ Protease Inhibitor Cocktail (Sigma) and 0.1% SDS for 1 h
on ice. Subsequently, the samples were centrifuged for 15min at
15,000 rpm at 4 C and the supernatant was harvested. The samples
were diluted in NuPAGE™ LDS Sample Buffer (Thermo Fisher Sci-
entiﬁc) prior to SDS-PAGE and subsequent transfer to a nitrocel-
lulose membrane. Proteins were detected using rabbit-anti-mouse
MMP-9 (1:1000, Abcam) and rabbit-anti-mouse b-actin (1:1000,
Novus Biologicals) antibodies.
2.8. Flow cytometry
Blood samples and spleens were collected upon sacriﬁce.
Erythrocytes were subsequently lysed using ACK lysis buffer to
prepare the leukocyte fraction for staining of surface markers. For
analysis of surface markers, cells were stained at 4 C for 30min in
PBS containing 2% (vol/vol) fetal bovine serum (FBS) with anti-
bodies from eBioscience and BD Biosciences (Supplementary table
2). Flow cytometric analysis was performed on a FACSCantoII (BD
Biosciences) and data was analyzed using Flowjo software
(TreeStar).
2.9. Serum analysis
For measurement of blood glucose levels, mice were fasted for
4 h prior to blood collection. Blood samples were taken from the tail
vein and directly applied to an Accu-Check glucometer (Roche Di-
agnostics). The levels of serum CCL2, insulin and mouse Amyloid A
were determined by ELISA according to manufacturer's protocol
(CCL2; BD Biosciences, insulin and mouse Amyloid A; Thermo
Fisher Scientiﬁc). Concentration of total cholesterol in the serum ofunfasted mice was determined by an enzymatic colorimetric assay
(Roche Dagnostics). Concentration of triglycerides in the serumwas
determined by an enzymatic colorimetric assay. Precipath (stan-
dardized serum, Roche Diagnostics) was used as an internal stan-
dard in the measurements for cholesterol and triglycerides.
2.10. Statistical analysis
Data are expressed as mean± SEM. Datasets were examined for
outliers using the ROUT method in GraphPad Prism version 7.00. A
two-tailed Student's t-test was used to compare individual groups
with Gaussian distributed data. Non-parametric data was analyzed
using aMann-Whitney U test. Data from three or more groups were
analyzed using a one-way ANOVA whereas data from three groups
with more than one variable were analyzed by a two-way ANOVA,
both with a subsequent Sidak multiple comparison test. A p-value
below 0.05 was considered signiﬁcant.
3. Results
3.1. Lcn2 mRNA expression during collar-induced atherosclerosis
To conﬁrm that Lcn2 expression is increased in atherosclerotic
carotid arteries as compared to healthy non-atherosclerotic carotid
arteries, we assessed Lcn2 expression levels by performing a
microarray on collar-induced atherosclerotic lesions from Western
type diet (WTD, 0.25% cholesterol and 15% cacao butter) fed Ldlr-/-
mice at different time points after collar placement. Herein, carotid
arteries from mice which were fed a WTD for 2 weeks but without
collar-induced atherosclerosis served as a control (t¼ 0). Lcn2
expression is sharply increased two weeks (t2) after collar place-
ment when compared to unaffected carotid arteries (Fig. 1A).
Although not as pronounced, Lcn2 expression remained elevated as
plaque development progresses four to ten weeks after collar
placement (Fig. 1A). In the same experiment, microarray analysis
revealed that the expression of the gene encoding the Lcn2 receptor
24p3r was unaltered during atherosclerosis (Fig. 1B). RT-qPCR
analysis of Lcn2 expression in atherosclerotic carotid arteries from
an additional collar-induced atherosclerosis experiment in Ldlr-/-
mice conﬁrmed that Lcn2 expression was elevated during collar-
induced atherosclerosis especially after 6, 8 and 10 weeks
(Fig. 1C). Importantly, RT-qPCR analysis of Lcn2 expression in ca-
rotid arteries from Ldlr-/- mice which were fed a normal chow diet
or a WTD showed that a WTD alone did not induce Lcn2 expression
(median± interquartile range; NCD: 0.0067± 0.009 vs. WTD:
0.013± 0.019, p¼ 0.35). 24p3r expression was also measured using
RT-qPCR and conﬁrmed to be unaltered during atherosclerosis
(Fig. 1D). Thus, atherosclerotic carotid arteries displayed higher
levels of Lcn2 expression as compared to non-atherosclerotic ca-
rotid arteries.
3.2. Metabolic health status of Ldlr/-Lcn2/ mice
To examine the effects of Lcn2 deﬁciency on atherosclerosis,
Ldlr-/- Lcn2-/- and Ldlr-/- mice were fed a WTD for 6 or 12 weeks. As
Lcn2 is associated with the development of metabolic diseases
which can contribute to atherosclerosis (e.g. obesity) various pa-
rameters of obesity and insulin resistance were examined. During
the experiment, Lcn2 deﬁciency resulted in a lower body weight
after 7 weeks of WTD but otherwise did not result in differences in
body weight (Fig. 2A). Accordingly, inguinal white adipose tissue
(iWAT) weight did not differ signiﬁcantly when comparing Ldlr-/-
Lcn2-/- mice to Ldlr-/- mice after 6 or 12 weeks of feeding WTD
(Fig. 2B). Total cholesterol levels in serum after 3, 6 or 12 weeks of
WTD showed no differences between Ldlr-/- Lcn2-/- mice and Ldlr-/-
Fig. 1. Lcn2, but not 24p3r, mRNA expression was increased in collar-induced atherosclerosis in Ldlr-/- mice.
(A) Microarray on carotid arteries of Ldlr-/- mice without (t¼ 0) or with collar-induced atherosclerosis showed Lcn2 expression was signiﬁcantly upregulated 2 weeks after collar
placement. Hereafter, it remained elevated from 4 until 10 weeks after collar placement, albeit less pronounced. (B) In the same microarray as in (A), expression of the Lcn2 receptor
24p3r was unaltered during plaque development. (C) In a parallel collar-induced atherosclerosis experiment, we performed RT-qPCR analysis of Lcn2 expression in the carotid
arteries of mice and Lcn2 expression was conﬁrmed to be elevated during atherosclerosis. (D) In accordance to (B), RT-qPCR analysis revealed that 24p3r expression was unaltered
during plaque development. n ¼ 3 per time point (A and B) and n ¼ 3e5 for (C and D). (*p<0.05, **p<0.01).
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were also equal between Ldlr/-Lcn2-/- mice and Ldlr/- mice
(Supplementary Fig.1A). Fasting glucose levels were also similar
between the groups at these time points (Fig. 2D). In line, insulin
levels were similar between both groups after both 6 and 12 weeks
of WTD feeding (Supplementary Fig.1B).
3.3. Atherosclerotic plaque formation in Ldlr-/-Lcn2-/- mice
Lcn2 expression in atherosclerotic plaques of aortic arches was
increased after 12 weeks WTD compared to 6 weeks WTD in the
Ldlr-/- group (Fig. 3A). After 6 weeks of WTD feeding, Ldlr-/- Lcn2-/-
mice developed ~20% larger plaques (Fig. 3B). The intraplaque
macrophage content as measured by MOMA2 staining was not
signiﬁcantly altered (Fig. 3C). Total neutrophil numbers in the
plaque and adventitiawere not signiﬁcantly different between both
groups (Fig. 3D). As compared to Ldlr-/- mice, Ldlr-/- Lcn2-/- mice had
higher intraplaque smooth muscle cell content as measured by
aSMA staining (Fig. 3E). The collagen content in the plaques was
equal between the two groups after 6 weeks of WTD (Fig. 3F).
Interestingly, as opposed to the effect on plaque size after 6 weeks
of diet feeding, plaque size after prolonged diet feeding was similar
in Ldlr-/- Lcn2-/- and Ldlr-/- mice after 12 weeks of WTD (Fig. 3G).
Plaques of Ldlr-/- Lcn2-/- did not differ signiﬁcantly from Ldlr-/- mice
in terms of MOMA2 staining (Supplementary Fig.2A), totalneutrophil numbers (Supplementary Fig.2B), or intraplaque
smooth muscle cell percentage (Supplementary Fig.2C) after 12
weeks of WTD. However, a reduction in acellular, necrotic area was
observed in advanced atherosclerotic lesions from Ldlr-/- Lcn2-/-
mice (Fig. 3G), which was not the case for atherosclerotic plaques
after 6 weeks ofWTD feeding (Supplementary Fig.2D). The collagen
content in advanced lesions was unalteredwhen comparing lesions
from Ldlr-/- Lcn2-/- to Ldlr-/- mice (Fig. 3H). The percentage of plaque
(plaque area/lumen area*100%) was not signiﬁcantly higher in
Ldlr-/- Lcn2-/- mice although it did show a trend towards being
higher after 6 (Supplementary Fig.2E) and 12 weeks of WTD
(Supplementary Fig.2F), suggesting outward remodeling occurred
as a response to atherosclerosis formation.
3.4. Effects of Lcn2 deﬁciency on the myeloid cell populations
during atherosclerosis
To establish whether Lcn2 deﬁciency has any effects on the
myeloid cell populations during atherosclerosis, ﬂow cytometry on
blood and spleen was performed. In line with our observation that
neutrophil numbers were unaltered in the lesions of Ldlr-/- Lcn2-/-
mice, no signiﬁcant changes were observed in circulating neutro-
phils after 6 weeks of WTD, neither in percentages nor in the C-X-C
chemokine receptor type 2 (CXCR2)þ subset (Fig. 4A). No signiﬁcant
changes in percentage of eosinophils, as deﬁned as
Fig. 2. Ldlr-/-Lcn2-/- mice were metabolically similar to Ldlr-/- mice.
(A) Ldlr/-Lcn2-/- mice showed a signiﬁcantly higher body weight as compared to Ldlr/ mice after seven weeks of WTD. Otherwise, no differences in weight were observed at
different time points. (B) In line with this, inguinal white adipose tissue (iWAT) was equal between both groups. (C) Total cholesterol levels in the serum were unaltered between
both groups. (D) Fasting glucose was measured over time. No signiﬁcant changes were observed between the Ldlr/-Lcn2-/- group and the Ldlr/- controls. n ¼ 10e12 per group. All
values are mean ± SEM. (*p<0.05).
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(Supplementary Fig.3A). The same results were obtained after 12
weeks of WTD (Supplementary Fig.3B). Interestingly, a higher
percentage of circulating Ly6Chi inﬂammatory monocytes was
measured after 6 weeks ofWTD. Inﬂammatorymonocytes followed
a similar trend after 12 weeks of WTD. Ly6Clo patrolling monocytes
were decreased accordingly after 6 weeks, although this did not
reach signiﬁcance after 12 weeks of WTD (Fig. 4A). No signiﬁcant
changes in myeloid cell or lymphocyte populations were observed
in the bone marrow compartment or draining lymph node of the
aortic root (data not shown). Together, these data indicate that the
circulating monocytes are skewed towards a pro-inﬂammatory
phenotype in the Ldlr-/- Lcn2-/- mice. Although not as pronounced
as in the blood, splenic monocytes were signiﬁcantly elevated as
well after 6 weeks WTD (Fig. 4B). Interestingly, serum amyloid A
levels in Ldlr-/- Lcn2-/- mice were higher as compared to Ldlr-/- mice
after 6 and 12 weeks of WTD (Supplementary Fig.3C) indicating
that Lcn2 deﬁciency alters the inﬂammatory status during athero-
genesis. To examine whether a relative increase in inﬂammatory
monocytes resulted in an increase in M1-like macrophages in the
plaque the mRNA expression of M1 markers (iNOS, TNFa, IL1b) and
M2markers (Arg1, Fizz, IL10) was measured. Lcn2 deﬁciency had no
effect on the expression of iNOS, TNFa and IL1b. Of the M2 markers,
only Fizz was elevated in the atherosclerotic aortic arch after 12
weeks of WTD (Fig. 4C). Similarly, after 6 weeks of WTD, Lcn2
deﬁciency resulted in increased Fizz expression in the aortic arch
while other M1 and M2 macrophage markers were unaltered(Supplementary Fig.3D). Expression of CCL2, a well-recognized
chemoattractant for inﬂammatory monocytes, which is also
known as MCP-1, was measured in atherosclerotic aortic arches to
examine whether increased monocyte recruitment was induced by
local expression of CCL2. The expression of CXCL1 (the mouse ho-
mologue of IL-8), an important chemoattractant for CXCR2þ neu-
trophils, was measured to conﬁrm that neutrophil recruitment to
atherosclerotic lesions was unaltered in Ldlr-/- Lcn2-/- mice. mRNA
expression of CCL2 and CXCL1were unaltered in the atherosclerotic
aortic arch (Fig. 4D). No signiﬁcant changes were observed in CCL2
levels in the serum when comparing Ldlr-/- Lcn2-/- mice to Ldlr-/- at
the 6 or 12 week time points (Fig. 4E).
3.5. MMP-9 activity in the aortic root
As a decreased necrotic core size in advanced atherosclerosis
could be due to decreased intraplaque proteolytic activity an in situ
zymography was performed to measure MMP-9 activity in athero-
sclerotic lesions in the aortic root. AnMMP-2 inhibitorwas added in
the reaction mix to ensure that DQ-gelatin degradation was mainly
MMP-9 mediated although some residual signal from other MMPs
with gelatinolytic activity may be present. A signiﬁcant decrease in
gelatinolytic activity, a measure for MMP activity, was observed in
the Ldlr-/- Lcn2-/- group compared to the control group (Fig. 5A).
MMP-9mRNA expression in the atherosclerotic aortic arch was not
signiﬁcantly different in Ldlr-/- Lcn2-/- mice compared to controls,
suggesting that the effects are primarily caused by MMP-9 protein
Fig. 3. Lcn2 deﬁciency affected atherosclerosis.
(A) Lcn2 expression in atherosclerotic plaques of aortic arches was increased after 12 weeks WTD compared to 6 weeks WTD in the Ldlr-/- group. (B) Lcn2 deﬁciency resulted in a
signiﬁcant increase in plaque size after 6 weeks WTD. (C) Macrophage content as a percentage of total plaque area measured by MOMA2 staining was unaltered. (D) Neutrophil
numbers in the plaque and adventitia showed no difference between both groups. (E) Smooth muscle cell percentage within the lesions was higher in the Ldlr-/- Lcn2-/- group as
compared to the controls. (F) Collagen content was equal between both groups. (G) Plaque size of advanced lesions was not signiﬁcantly different. (H) Necrotic core size was
signiﬁcantly decreased in advanced lesions. (I) Collagen content in advanced lesions was equal between both groups. n ¼ 6 per group for (A). n ¼ 12 for (BeH). All values are
mean ± SEM (*p<0.05).
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Fig. 4. Analysis of myeloid cell populations.
(A) Gating strategies for neutrophils, eosinophils and monocytes. Circulating neutrophil and eosinophil abundance was unaltered. Neutrophils had similar expression levels to the
homing receptor CXCR2. Inﬂammatory monocytes were increased in Ldlr-/- Lcn2-/- mice after 6 weeks of WTD with concomitant decreases in patrolling monocytes. (B) The splenic
inﬂammatory monocyte population showed a similar increase in Ldlr-/- Lcn2-/- mice. (C) mRNA expression of the M2 macrophage marker Fizz was elevated in the atherosclerotic
arch of Ldlr-/- Lcn2-/- mice as compared to Ldlr-/- mice. (D) mRNA expression of CCL2 and CXCL1 was unaltered in the atherosclerotic aortic arch. (E) No signiﬁcant differences were
observed in serum CCL2 levels between both groups. n ¼ 6 per group. All values are mean ± SEM (*p<0.05, **p<0.01, ***p<0.001).
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showed that MMP-9 protein expression was equal between Ldlr-/-
and Ldlr-/- Lcn2-/- mice (Fig. 5C) and quantiﬁcation of the blot
conﬁrmed this (Supplementary Fig.4A). Furthermore, the ratio be-
tween the pro- and active form of theMMP-9 proteinwas unaltered
between both genotypes (Supplementary Fig.4B). Interestingly, no
differences in MMP-2 mRNA expression (Supplementary Fig.4C) or
MMP-14mRNA expression (Supplementary Fig.4D) in the athero-
sclerotic aortic arches were observed when comparing Ldlr-/- mice
to Ldlr-/- Lcn2-/-. In line with a decreased necrotic core size, lesions
from Ldlr-/- Lcn2-/-mice contained fewer apoptotic cells. The number
of apoptotic macrophages was equal between both genotypes
(Fig. 5D).
4. Discussion
Several studies reported that the detection of unstable athero-
sclerotic plaques using Lcn2 could prove useful in the future to
reduce the incidence of acute cardiovascular syndromes, however
the direct contribution of Lcn2 to atherosclerotic plaque progres-
sion remained up to date uninvestigated.
Microarray analysis of non-constrictive collar-induced athero-
sclerosis showed that local Lcn2 expression increased during early
stages of atherosclerotic lesion development, and remained
elevated during plaque progression. As expression of the Lcn2-
receptor 24p3r was unaltered, local Lcn2 effects in atherosclerotic
plaques were mainly regulated by regulating the expression of the
protein itself or by regulating the inﬂux of myeloid cells expressing
Lcn2, such as neutrophils and monocytes. Based on these ﬁndings
we studied the effect of Lcn2 deﬁciency on different stages of
atherosclerosis and related this to changes in myeloid cell pop-
ulations. After 6 weeks of WTD, lesions from Ldlr-/- Lcn2-/- were
somewhat larger and had a higher smooth muscle cell percentage
as compared to those of Ldlr-/- control mice, but plaque composition
remained otherwise unaltered. Interestingly, Lcn2 deﬁciency did
not affect advanced lesion size but did display a decrease in necrotic
area.
The effects observed on plaque size could not be explained by
increased hepatic steatosis and resulting increases in circulating
cholesterol levels. A study by Ye et al. described Lcn2 to exert pro-
inﬂammatory effects in a high fat, high cholesterol diet induced
model of non-alcoholic steatohepatitis (NASH) [27]. Lcn2 deﬁciency
in mice attenuated the transition of hepatic steatosis to NASH
whereas administration of recombinant Lcn2 exacerbated disease
in a neutrophil-dependent manner. In the present study, Ldlr-/-
Lcn2-/- mice showed no differences in total serum cholesterol or
circulating neutrophils which makes it unlikely that hepatic stea-
tosis contributed to the observed lesion effects. Ldlr-/- Lcn2-/- mice
were fed a WTD to study atherosclerosis, while a high fat high
cholesterol diet was used to study NASH. Presumably, the fact that
this diet contains 40% fat and was fed to the mice for 12e20 weeks
to induce NASH explains why Lcn2 deﬁciency did not affect the
development of hepatic steatosis in the present study.
In this study, Lcn2 deﬁciency had no effects on body weight or
iWATweight. Feeding a high fat diet to C57BL/6mice has previously
been shown to increase Lcn2 expression by adipocytes and to in-
crease its abundance in serum [28]. These increases are even more
pronounced in iWAT compared to epididymal WAT [29]. Further-
more, Lcn2 expression by adipocytes is induced by various pro-
inﬂammatory cytokines which are known to play a role in obesity
development, including TNFa, IL1-b and IL-6 [30]. Interestingly,
Lcn2 deﬁcient mice which are fed a high fat diet gain more weight
compared towildtypemice [29]. These effects were not observed in
our study, possibly due to the fact that our study used female mice
whereasmost studies on the role of Lcn2 in obesity were performedin male mice. Additionally, feeding a WTD for 6 or 12 weeks might
not have induced a severe enough obese phenotype to observe
differences between Lcn2 wildtype or Lcn2 deﬁcient mice. LDLr
deﬁcient mice develop hyperglycemia and insulin resistance after
approximately 20 weeks of feeding them a WTD [31] and Lcn2 has
been shown to affect insulin resistance [19]. The fact that fasting
glucose levels were equal between Ldlr-/- and Ldlr-/- Lcn2-/- mice
suggest that in the present study the time frame was too limited to
induce obesity and insulin resistance. As the metabolic parameters
we examined did not differ between both genotypes it is improb-
able that atherosclerosis was affected by altered metabolic disease
development in Ldlr-/- Lcn2-/- mice.
After 6 weeks ofWTD, lesions in Ldlr-/- Lcn2-/- mice were slightly
larger compared to Ldlr-/- control mice. This ﬁnding was rather
counterintuitive as Lcn2 is generally considered to be secreted
under and promote inﬂammatory conditions [19]. Interestingly,
there are actually also multiple studies describing Lcn2 to be pro-
tective in a number of inﬂammatory diseases. Lcn2 deﬁcient mice
have for example increased liver damage in various models for liver
injury with concomitant increases in expression of pro-
inﬂammatory factors such as CCL2, TNFa and a decrease in IL-10
expression [32]. Additionally, Lcn2 appears to play a protective role
in experimental autoimmune encephalomyelitis pathogenesis as
Lcn2 deﬁcient mice have higher lesion burden and increased
expression of IFNg and TNFa inside lesions [33]. In our study, Lcn2
deﬁciency did not affect the expression of TNFa, CCL2 in the
atherosclerotic aortic arches, suggesting Lcn2 exerts a protective
function in atherogenesis which is distinct from other diseases.
Upon Lcn2 deﬁciency, circulating monocytes were skewed towards
a more inﬂammatory phenotype, which may have driven lesion
progression, considering the atherogenic effects inﬂammatory
monocytes have on early lesion development [34]. No differences
were however observed in macrophage content of the plaques.
When plaques from the aortic arch were analyzed for different M1
and M2macrophage marker expression, it was shown that only the
M2marker Fizzwas elevated in Lcn2 deﬁcientmice. The phenotypic
effects that Lcn2 has on macrophages appear to be condition-
speciﬁc as different studies have reported treatment of bone
marrow-derived macrophages (BMDM) with Lcn2 to increase
expression of M1 markers [35] but also IL-10 production [36].
Furthermore, BMDM from Lcn2-/- mice showed a more profound
upregulation of IL-1b and iNOS after lipopolysaccharide stimulation
compared to wildtype controls [37] whereas infection of Lcn2
deﬁcient peritoneal macrophages with Salmonella Typhimurium
was reported to result in increased IL-10 expression as compared to
wildtype controls [38]. In the presented study, as Lcn2 can induce
foam cell formation in BMDM by inducing the expression of scav-
enger receptors [35], the absence of Lcn2 might have compensated
for increased monocyte homing towards atherosclerotic lesions. It
is unclear what causes the increase in monocyte activation. Lcn2 is
known to interact with LTB4, which acts as a chemokine for
monocytes during development of atherosclerosis [39], but it is
unknown what functional consequences this interaction has [4].
The absence of Lcn2 may have increased the potency of LTB4 to
activate monocytes, however future studies should shed more light
on exact mechanisms involved in Lcn2 mediated monocyte differ-
entiation and migration.
Based on the results, Lcn2 did not function as a chemoattractant
for neutrophils to home towards atherosclerotic lesions in this
study as neither the number of neutrophils inside the plaques nor
the circulating neutrophil percentages were changed. Lcn2 has
been shown to serve as a chemoattractant for neutrophils during
acute inﬂammation [5] and during development of NASH by
increasing CXCR2-dependent homing towards the liver [27]. Lcn2
deﬁciency had no effect on CXCL1 expression in atherosclerotic
Fig. 5. Assessment of MMP-9 activity in atherosclerotic plaques.
(A) MMP-9 activity in the aortic root as measured by an in situ zymography was decreased in Lcn2 deﬁcient mice. (B)MMP-9 gene expression in atherosclerotic lesions of the aortic
arch was equal between both groups. (C) Similarly, protein expression of MMP-9 was similar between both groups. (D) Lesions from Ldlr-/- Lcn2-/- mice contained fewer apoptotic
cells per section but not fewer apoptotic macrophages (MF) as compared to lesions from Ldlr-/- mice. In (A), gelatinolytic activity is visualized in green and nuclei are stained in dark
blue. The white arrows indicate regions with high enzymatic activity. In (D), TUNEL positive nuclei of apoptotic cells are depicted in light blue (indicated with a white arrow) and
TUNEL positive nuclei of apoptotic macrophages are depicted in white (indicated with a white arrow and asterisk). Macrophage positive area is depicted in red and nuclei in dark
blue. The data in (A) is representative of two experiments. n ¼ 10 (A and C). n ¼ 6 (5 B). All values are mean ± SEM (*p<0.05, **p<0.01). (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the Web version of this article.)
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neutrophil recruitment to atherosclerotic plaques in this study. As
compared to Lcn2 levels during acute inﬂammation, the levels of
circulating and local Lcn2 during atherogenesis might not be high
enough for Lcn2 deﬁciency to alter neutrophil recruitment, possibly
explaining why Lcn2 deﬁciency during experimental atheroscle-
rosis had no effect on neutrophil migration.
In advanced atherosclerotic plaques, Ldlr-/- Lcn2-/- mice did show
a decreased necrotic core area inside lesions of the aortic root,
suggesting that Lcn2 deﬁciency affected matrix degradation. This
was most likely due to the decreased local MMP-9 activity in the
Lcn2 deﬁcient mice as measured by zymography. Lcn2 binds to
MMP-9 to prevent its inhibition by tissue inhibitor of metal-
loproteinases [6], leading to more active MMP-9. Proteolytic ac-
tivity has been shown to induce the apoptosis of macrophages and
smooth muscle cells and inhibition of proteolytic activity can
decrease necrotic core size accordingly [40e42]. As lesions from
Lcn2 deﬁcient mice contained fewer apoptotic cells, a decreased
necrotic core size in lesions from Lcn2 deﬁcient mice could be due
to a decrease in MMP activity and subsequent proteolysis-induced
apoptosis. Previously, Lcn2 and MMP-9 have been shown to
colocalize in atherosclerotic lesions [18]. As MMP9 expression in-
side atherosclerotic lesions of the aortic arch was equal between
the Ldlr-/- Lcn2-/- and control groups, the decrease inMMP-9 activity
in the Lcn2 deﬁcient mice was unlikely due to decreased MMP-9
abundance, but mainly caused by decreased MMP-9 activity.
These ﬁndings are in line with literature describing unstable pla-
ques to have higher levels of NGAL than stable plaques [17] and
support serum NGAL/MMP-9 complex levels to predict MACE 1
year after follow up [13]. The present study provides evidence that
local Lcn2 in advanced stages of atherosclerosis might indeed
decrease lesion stability. Whether Lcn2 actually affects lesion sta-
bility in advanced atherosclerosis or it only modulates MMP-9 ac-
tivity and necrotic core size remains to be determined.
Nevertheless, our ﬁndings suggest that lowering of NGAL levels
through therapeutic intervention might be feasible to increase
plaque stability in patients with unstable atherosclerosis as the
presence of NGAL in advanced atherosclerosis appears to
contribute to plaque instability. Interestingly, in patients with ca-
rotid artery atherosclerosis, serum NGAL levels were lower in pa-
tients on statins as compared to patients without. Also in patients
with vulnerable lesions, statin-treated patients had lower levels of
serum NGAL compared to patients without statins [15]. Another
study in patients which underwent carotid endarterectomy as a
treatment for advanced atherosclerosis showed that serum NGAL
levels were equal between patients with or without statin treat-
ment [43]. This suggests that statin treatment can decrease circu-
lating NGAL levels but that this may depend on the patient group
which is targeted.
There are some limitations to this study. For example, plaque
sizewas determined in the aortic root but not at other sites of lesion
development. Another limitation is that we did not perform an oral
glucose tolerance test to examine the effects Lcn2 deﬁciency has on
the metabolic health status in these experiments. As this is a highly
relevant parameter in assessing the metabolic syndrome-like
phenotype diet-induced dyslipidemia can induce, it is not
possible to deﬁnitely conclude that Lcn2 deﬁciency had no effects
on the metabolic status in our experiments. However, as the total
body weight, iWAT weight, fasting glucose and insulin levels in the
serum were unaltered between groups it is highly unlikely that
Lcn2 deﬁciency had any effect on the metabolic health status in
these experiments. Lastly, in our zymography, other MMPs besides
MMP-9 which can degrade gelatin might have caused some back-
ground signal. However, areas with high gelatinolytic activity have
been shown to colocalize with MMP-9 [18], indicating thegelatinolytic activity which we measured was mainly MMP-9
derived.
In conclusion, Lcn2 deﬁciency was shown to increase plaque
size during earlier stages of lesion development, possibly due to an
increase in inﬂammatory monocytes and without affecting
neutrophil recruitment. In addition, this study showed that Lcn2
deﬁciency decreased the local degree of MMP-9 activity thereby
possibly contributing to more stable atherosclerotic plaques.
Further studies are required to further examine the effects of Lcn2
on myeloid cell populations during atherogenesis as this might
further improve the interpretation of changes in circulating Lcn2
levels.
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